Abstract
IntroductionMetabolic syndrome (MS) is associated with several cancers, but it is not clear whether MS affects the prognosis of tongue squamous cell carcinoma (TSCC). This study aimed to evaluate the prognostic value of MS in TSCC.MethodsClinical data from 252 patients with TSCC who were initially treated at the Sun Yat-sen University Cancer Center between April 1998 and June 2011 were collected, and the associations between MS and clinicopathologic factors were retrospectively analyzed. Prognostic outcomes were examined by Kaplan-Meier analysis and Cox regression analysis.ResultsOf the 252 patients, 48 were diagnosed with MS. MS was associated with early N category in TSCC (P < 0.001). The patients with MS showed longer survival than those without MS (P = 0.028). MS was an independent prognostic factor for patients with TSCC.ConclusionsMS is associated with early N category in TSCC. It is an independent prognostic factor for better survival in patients with TSCC.
Highlights
Metabolic syndrome (MS) is associated with several cancers, but it is not clear whether MS affects the prognosis of tongue squamous cell carcinoma (TSCC)
Our study demonstrated that MS was associated with early N category in TSCC
Previous reports demonstrated that MS was associated with better differentiation in gastric cancer cells [9], whereas others indicated that MS or its components were associated with a more aggressive tumor type in colon cancer and prostate cancer [11,12]; the influence of MS on breast cancer remains controversial [13,14]
Summary
Metabolic syndrome (MS) is associated with several cancers, but it is not clear whether MS affects the prognosis of tongue squamous cell carcinoma (TSCC). Oral squamous cell carcinoma (OSCC) is a common malignant tumor worldwide. Tongue squamous cell carcinoma (TSCC) is especially prevalent in lowincome communities in North France, East Europe, South America, and Southeast Asia, and 90% of patients with TSCC are over 45 years old [3]. TSCC seriously affects quality of life of the patients and carries a poor prognosis, with a 5-year overall survival (OS) rate of 56% [4]. MS and its components are associated with worse survival in breast cancer [7] and prostate cancer [8], but better survival for gastric cancer [9].
Sign-in/Register to view highlights & summary 
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call